Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Frequently asked questions
What sector does Mycenax Biotech (4726) operate in?
Mycenax Biotech belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Mycenax Biotech (4726) current stock price?
As of the latest data, Mycenax Biotech stock price is NT$24.35, with a previous close of NT$24.35.
What is Mycenax Biotech (4726) current market capitalization?
Mycenax Biotech market cap is approximately 5.04 billion.
What is Mycenax Biotech (4726) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.11.
Does Mycenax Biotech (4726) pay dividends?
No. Mycenax Biotech does not pay a dividend.
What is Mycenax Biotech (4726) beta (volatility) score?
Mycenax Biotech has a beta of 0.450, indicating lower volatility than the overall market.
